| Literature DB >> 18376118 |
Stephen M S Ting1, Douglas Lee, Douglas Maclean, Neil S Sheerin.
Abstract
Flecainide is a sodium channel blocker used mainly in the treatment of supraventricular arrhythmias. Central nervous system side effects such as dizziness, visual disturbances, headache and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. We report the first case of flecainide toxicity in a patient with end-stage renal failure. Cessation of flecainide therapy resulted in a fall in serum flecainide levels, with associated resolution of adverse central nervous system effects. We also review the pharmacokinetics of flecainide in patients with chronic kidney disease. Copyright 2008 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18376118 DOI: 10.1159/000119694
Source DB: PubMed Journal: Cardiology ISSN: 0008-6312 Impact factor: 1.869